Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
| Autor: | David Michelson, Robert S. Stern, Christopher Randolph, Paul S. Aisen, Craig Shering, Nicole Dupre, Alette M. Wessels, Christopher Lines, James Kost, Bruno Vellas, Lyn Harper Mozley, Pierre N. Tariot, Tiffini Voss, Michael F. Egan, Christine Furtek, Yuki Mukai, John R. Sims, Jeffrey L. Cummings, Scott W. Andersen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Repeatable Battery for the Assessment of Neuropsychological Status Epidemiology Disease Audiology 03 medical and health sciences Cellular and Molecular Neuroscience Fluency 0302 clinical medicine Cognition Developmental Neuroscience Double-Blind Method Alzheimer Disease medicine Verbal fluency test Humans Spiro Compounds Episodic memory Aged Thiadiazines business.industry Health Policy Imidazoles Cyclic S-Oxides Clinical trial Psychiatry and Mental health 030104 developmental biology Treatment Outcome Verubecestat Female Neurology (clinical) Geriatrics and Gerontology business 030217 neurology & neurosurgery |
| Zdroj: | Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES. 16(11) |
| ISSN: | 1552-5279 |
| Popis: | Introduction The APECS and AMARANTH trials showed that beta-secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on secondary and exploratory cognitive measures in both studies is reported. Methods APECS (verubecestat) and AMARANTH (lanabecestat) were randomized, double-blind, placebo-controlled, parallel-group, 104-week clinical trials conducted by different sponsors. Measures included the 3-Domain Composite Cognition Score (CCS-3D), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Letter/Category Fluency, and Digit Symbol Coding. Results Verubecestat showed worsening on the CCS-3D Total Score, Episodic Memory, and Attention/Processing Speed domains. Lanabecestat showed worsening on the RBANS Total Score, Immediate Memory, and Visuospatial/Constructional Indexes. Both BACE inhibitors showed worsening on Digit Symbol Coding and improvements on Letter/Category Fluency. Discussion In both studies, many measures showed treatment-associated cognitive worsening, whereas verbal fluency tasks showed improvement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|